Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer
| Type of Publication: | Journal article |
| Publication status: | Published |
| Author: | Kulkarni, Bhagyashri; Kirave, Prathibha; Gondaliya, Piyush; Jash, Kavya; Jain, Alok; Tekade, Rakesh K.; Kalia, Kiran |
| Year of publication: | 2019 |
| Published in: | Drug discovery today ; 24 (2019), 10. - pp. 2058-2067. - ISSN 1359-6446. - eISSN 1878-5832 |
| Pubmed ID: | 31228614 |
| DOI (citable link): | https://dx.doi.org/10.1016/j.drudis.2019.06.010 |
| Summary: |
In the treatment of cancer, there are three significant limitations causing high mortality and recurrence rates among cancer patients. First, the escape of tumor cells from the immune system; second, the development of multi-drug resistance (MDR) to chemotherapeutic drugs; and, third, the noxious metastases of cancer cells. Exosomes are vesicular cargos involved in the transportation of miRNA, mRNA and proteins from one cell to another cell. This review details the current understanding of the exosomal transmission of miRNA and crosstalk with the downstream consequences, ultimately leading to the progression and metastasis of cancer. Further, this review also discusses how exosomal miRNA can provide promising novel targets for the treatment and detection of cancer.
|
| Subject (DDC): | 540 Chemistry |
| Refereed: | Yes |
Cite This
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
KULKARNI, Bhagyashri, Prathibha KIRAVE, Piyush GONDALIYA, Kavya JASH, Alok JAIN, Rakesh K. TEKADE, Kiran KALIA, 2019. Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. In: Drug discovery today. 24(10), pp. 2058-2067. ISSN 1359-6446. eISSN 1878-5832. Available under: doi: 10.1016/j.drudis.2019.06.010
@article{Kulkarni2019-10Exoso-46240, title={Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer}, year={2019}, doi={10.1016/j.drudis.2019.06.010}, number={10}, volume={24}, issn={1359-6446}, journal={Drug discovery today}, pages={2058--2067}, author={Kulkarni, Bhagyashri and Kirave, Prathibha and Gondaliya, Piyush and Jash, Kavya and Jain, Alok and Tekade, Rakesh K. and Kalia, Kiran} }
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/46240"> <dc:creator>Jain, Alok</dc:creator> <dc:contributor>Jash, Kavya</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-05T13:12:47Z</dcterms:available> <dc:contributor>Jain, Alok</dc:contributor> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/46240"/> <dc:contributor>Gondaliya, Piyush</dc:contributor> <dc:creator>Kulkarni, Bhagyashri</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <dc:creator>Jash, Kavya</dc:creator> <dc:contributor>Tekade, Rakesh K.</dc:contributor> <dc:contributor>Kulkarni, Bhagyashri</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <dc:contributor>Kirave, Prathibha</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-05T13:12:47Z</dc:date> <dc:creator>Kalia, Kiran</dc:creator> <dc:language>eng</dc:language> <dcterms:issued>2019-10</dcterms:issued> <dcterms:abstract xml:lang="eng">In the treatment of cancer, there are three significant limitations causing high mortality and recurrence rates among cancer patients. First, the escape of tumor cells from the immune system; second, the development of multi-drug resistance (MDR) to chemotherapeutic drugs; and, third, the noxious metastases of cancer cells. Exosomes are vesicular cargos involved in the transportation of miRNA, mRNA and proteins from one cell to another cell. This review details the current understanding of the exosomal transmission of miRNA and crosstalk with the downstream consequences, ultimately leading to the progression and metastasis of cancer. Further, this review also discusses how exosomal miRNA can provide promising novel targets for the treatment and detection of cancer.</dcterms:abstract> <dc:creator>Tekade, Rakesh K.</dc:creator> <dc:creator>Kirave, Prathibha</dc:creator> <dcterms:title>Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer</dcterms:title> <dc:contributor>Kalia, Kiran</dc:contributor> <dc:creator>Gondaliya, Piyush</dc:creator> </rdf:Description> </rdf:RDF>
This item appears in the following Collection(s)
Search KOPS
Browse
My Account
